PMID- 22059982
OWN - NLM
STAT- MEDLINE
DCOM- 20120207
LR  - 20211021
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 9
DP  - 2011 Nov 7
TI  - A case of HER-2-positive recurrent breast cancer showing a clinically complete 
      response to trastuzumab-containing chemotherapy after primary treatment of 
      triple-negative breast cancer.
PG  - 146
LID - 10.1186/1477-7819-9-146 [doi]
AB  - We report a case of HER-2-positive recurrent breast cancer showing a clinically 
      complete response to trastuzumab-containing chemotherapy 6 years after primary 
      treatment of triple-negative breast cancer. The primary tumor was negative for 
      HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH) (1+, and ratio, 1.1), but examination of the recurrent lymph 
      node metastasis showed positivity for HER-2 by FISH (ratio, 5.2). No lesions were 
      detected in either her left breast or in other organs, and the patient was 
      diagnosed as having HER-2-positive recurrent disease. Combination chemotherapy 
      using weekly paclitaxel and trastuzumab was initiated, and a clinically complete 
      response was achieved. This report suggests the benefit of routine evaluation of 
      HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting 
      agents.
FAU - Shigematsu, Hideo
AU  - Shigematsu H
AD  - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. 
      shigematu1330@yahoo.co.jp
FAU - Kadoya, Takayuki
AU  - Kadoya T
FAU - Kobayashi, Yoshie
AU  - Kobayashi Y
FAU - Kajitani, Keiko
AU  - Kajitani K
FAU - Sasada, Tatsunari
AU  - Sasada T
FAU - Emi, Akiko
AU  - Emi A
FAU - Masumoto, Norio
AU  - Masumoto N
FAU - Haruta, Rumi
AU  - Haruta R
FAU - Kataoka, Tsuyoshi
AU  - Kataoka T
FAU - Oda, Miyo
AU  - Oda M
FAU - Arihiro, Kouji
AU  - Arihiro K
FAU - Okada, Morihito
AU  - Okada M
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20111107
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*drug therapy/metabolism/pathology
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/metabolism/pathology
MH  - Paclitaxel/administration & dosage
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Progesterone/*metabolism
MH  - Remission Induction
MH  - Trastuzumab
MH  - Treatment Outcome
PMC - PMC3220638
EDAT- 2011/11/09 06:00
MHDA- 2012/02/09 06:00
PMCR- 2011/11/07
CRDT- 2011/11/09 06:00
PHST- 2011/06/22 00:00 [received]
PHST- 2011/11/07 00:00 [accepted]
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/02/09 06:00 [medline]
PHST- 2011/11/07 00:00 [pmc-release]
AID - 1477-7819-9-146 [pii]
AID - 10.1186/1477-7819-9-146 [doi]
PST - epublish
SO  - World J Surg Oncol. 2011 Nov 7;9:146. doi: 10.1186/1477-7819-9-146.